KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Gains from Investment Securities: 2017-2025

Historic Gains from Investment Securities for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $129,000.

  • Amneal Pharmaceuticals' Gains from Investment Securities rose 111.19% to $129,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year increase of 2927.02%. This contributed to the annual value of $15.2 million for FY2024, which is 204.99% up from last year.
  • According to the latest figures from Q3 2025, Amneal Pharmaceuticals' Gains from Investment Securities is $129,000, which was down 31.75% from $189,000 recorded in Q2 2025.
  • Amneal Pharmaceuticals' Gains from Investment Securities' 5-year high stood at $22.6 million during Q4 2022, with a 5-year trough of -$27.1 million in Q4 2021.
  • Its 3-year average for Gains from Investment Securities is $2.1 million, with a median of $496,000 in 2023.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Gains from Investment Securities plummeted by 621.89% in 2023, and later soared by 504.23% in 2024.
  • Over the past 5 years, Amneal Pharmaceuticals' Gains from Investment Securities (Quarterly) stood at -$27.1 million in 2021, then spiked by 183.24% to $22.6 million in 2022, then plummeted by 135.97% to -$8.1 million in 2023, then spiked by 175.85% to $6.2 million in 2024, then soared by 111.19% to $129,000 in 2025.
  • Its Gains from Investment Securities stands at $129,000 for Q3 2025, versus $189,000 for Q2 2025 and $21.6 million for Q1 2025.